[go: up one dir, main page]

MX2022015959A - Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. - Google Patents

Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Info

Publication number
MX2022015959A
MX2022015959A MX2022015959A MX2022015959A MX2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A MX 2022015959 A MX2022015959 A MX 2022015959A
Authority
MX
Mexico
Prior art keywords
fxi
antigen
binding fragment
fxia antibody
pharmaceutical use
Prior art date
Application number
MX2022015959A
Other languages
English (en)
Inventor
Jin Zhang
Xiao Liu
Lei Wang
Changyong Yang
Yang Yang
Ran Wu
Xugang He
Dongmei Hu
Yanping Du
Chenxi Shen
Original Assignee
Beijing Tuo Jie Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tuo Jie Biopharmaceutical Co Ltd filed Critical Beijing Tuo Jie Biopharmaceutical Co Ltd
Publication of MX2022015959A publication Critical patent/MX2022015959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un anticuerpo anti-FXI/FXIa, un fragmento del mismo que se une al antígeno y un uso farmacéutico del mismo, así como una composición farmacéutica que comprende el anticuerpo anti-FXI/FXIa o el fragmento del mismo que se une al antígeno, y un método para tratar y prevenir una enfermedad, en particular un método para tratar la trombosis o enfermedades o trastornos relacionados con el tromboembolismo.
MX2022015959A 2020-07-02 2021-07-02 Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. MX2022015959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010633951 2020-07-02
PCT/CN2021/104253 WO2022002249A1 (zh) 2020-07-02 2021-07-02 抗FXI/FXIa抗体、其抗原结合片段及医药用途

Publications (1)

Publication Number Publication Date
MX2022015959A true MX2022015959A (es) 2023-01-24

Family

ID=79317479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015959A MX2022015959A (es) 2020-07-02 2021-07-02 Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.

Country Status (11)

Country Link
US (1) US20230220111A1 (es)
EP (1) EP4177274A4 (es)
JP (1) JP7807081B2 (es)
KR (1) KR20230034361A (es)
CN (3) CN117487016A (es)
AU (1) AU2021302202A1 (es)
BR (1) BR112022026533A2 (es)
CA (1) CA3184718A1 (es)
MX (1) MX2022015959A (es)
TW (1) TWI882142B (es)
WO (1) WO2022002249A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
TW202333789A (zh) * 2022-01-05 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
WO2026017079A1 (zh) * 2024-07-16 2026-01-22 上海祥耀生物科技有限责任公司 抗fxi抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
ES2307832T3 (es) 2001-12-03 2008-12-01 Amgen Fremont Inc. Clasificacion de anticuerpos basada en las caracteristicas de union.
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
HRP20170374T1 (hr) 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
LT2373691T (lt) * 2008-12-18 2019-05-27 Oregon Health & Science University Anti-fxi antikūnai ir jų panaudojimo būdai
BRPI0924058B1 (pt) * 2008-12-22 2021-08-17 Novo Nordisk A/S Anticorpos monoclonais, seus usos, bem como composição farmacêutica
WO2013167669A1 (en) * 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CN108137705B (zh) * 2015-07-21 2022-11-08 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
AU2017236063B2 (en) * 2016-03-23 2024-06-13 Prothix Bv Monoclonal antibodies against the active site of factor XI and uses thereof
GB201609742D0 (en) * 2016-06-03 2016-07-20 Medical Res Council Technology Improvements relating to antibodies
TWI802193B (zh) * 2016-06-14 2023-05-11 美商默沙東有限責任公司 抗凝血因子ｘｉ抗體
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US12258419B2 (en) * 2019-04-16 2025-03-25 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-FXI/FXIa antibody and use thereof
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Also Published As

Publication number Publication date
JP7807081B2 (ja) 2026-01-27
CN117487017A (zh) 2024-02-02
CA3184718A1 (en) 2022-01-06
WO2022002249A1 (zh) 2022-01-06
CN114269790A (zh) 2022-04-01
TW202214701A (zh) 2022-04-16
KR20230034361A (ko) 2023-03-09
EP4177274A4 (en) 2024-04-03
US20230220111A1 (en) 2023-07-13
AU2021302202A1 (en) 2023-02-16
CN117487016A (zh) 2024-02-02
CN114269790B (zh) 2023-11-24
BR112022026533A2 (pt) 2023-01-17
EP4177274A1 (en) 2023-05-10
TWI882142B (zh) 2025-05-01
JP2023532251A (ja) 2023-07-27

Similar Documents

Publication Publication Date Title
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112021011684A2 (pt) Terapia combinada com cd70 e venetoclax, um inibidor de bcl-2, para o tratamento da leucemia mieloide aguda
MX2022015959A (es) Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
JOP20190002A1 (ar) أجسام مضادة (أنتي – بي دي – 1) وطريقة الإنتاج وطريقة استخدام كل منهم
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
JO2576B1 (en) Antibodies
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
PH12021551421A1 (en) Tubulysins and protein-tubulysin conjugates
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
PH12022552725A1 (en) Anti-ox40 antibody and uses thereof
ZA202309150B (en) Antibody against nkp46 and application of antibody
ZA202200906B (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
MX2022008471A (es) Anticuerpo anti-angptl3 y uso del mismo.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
MX2024005430A (es) Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.